Skip to main
IVVD

Invivyd Inc (IVVD) Stock Forecast & Price Target

Invivyd Inc (IVVD) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Invivyd Inc. is positioned favorably within the clinical-stage biopharmaceutical sector, developing innovative antibody-based therapies aimed at combating infectious diseases, particularly with a focus on COVID-19. The company's lead candidates, ADG20 and VYD222, utilize cutting-edge technologies that enhance their antiviral potency and longevity, with VBY329 demonstrating significant improvements in neutralization against resistant variants compared to existing treatments. Coupled with a robust market potential projected to expand to $3-4 billion globally by 2030 and supportive Phase 1/2 safety data, these factors contribute to a positive outlook on Invivyd's stock trajectory.

Bears say

Invivyd Inc operates in the competitive clinical-stage biopharmaceutical sector, focusing on antibody-based therapies aimed at infectious diseases. Despite a substantial total addressable market of approximately $4 billion for COVID-19 vaccines in 2024, challenges arise from the limitations of existing vaccines highlighted by management, including waning antibody responses and public hesitancy. The company's reliance on engineered immunity as a solution may face skepticism, pointing to risks in achieving widespread adoption and commercial viability, contributing to a negative outlook on its stock.

Invivyd Inc (IVVD) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Invivyd Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Invivyd Inc (IVVD) Forecast

Analysts have given Invivyd Inc (IVVD) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Invivyd Inc (IVVD) has a Strong Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Invivyd Inc (IVVD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.